REM-0046127 is under clinical development by ReMYND and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how REM-0046127’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

REM-0046127 overview

REM-0046127 is under development for the treatment of Alzheimer's disease (AD). The therapeutic candidate is a small molecule. It acts by targeting tau protein. The program carries the aim to decelerate or even stop cellular degeneration in protein misfolding disorders, such as Alzheimer's. It is administered through oral route.

ReMYND overview

reMYND is a contract research organization that develops disease modifying treatments for protein misfolding disorders. The company provides services such as contract research and drug discovery. Its contract research offers services related to pharmacokinetics with a focus on pre-clinical in vivo testing of all experimental alzheimer disease, parkinson disease, type 2 diabetes mellitus, several orphan diseases, and others. reMYND also provides transgenic mouse models of Alzheimer’s disease in the pharmacological assessment of treatments. The company’s CRO technology platform also concentrates on protein-misfolding disorders such as Huntington’s disease and amyotrophic lateral sclerosis to discover and develop drug candidates. reMYND is headquartered in Leuven, Brabant Flamand, Belgium.

For a complete picture of REM-0046127’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.